Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 14/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GCK | P35557 | 1/20 | 0.43 |
| ▸ | GCKR | Q14397 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14199470 | 0.92 | HSD11B1 (0.57) | HSD11B1GAAELANE | |
| SCHEMBL19222956 | 0.90 | HSD11B1 (0.65) | HSD11B1ALDH1A1 | |
| SCHEMBL6862811 | 0.84 | HSD11B1 (0.53) | HSD11B1GAAALDH1A1 | |
| SCHEMBL13239460 | 0.84 | ENPP2 (0.54) | HSD11B1ALDH1A1 | |
| SCHEMBL3637984 | 0.82 | CA2 (0.55) | HSD11B1 | |
| SCHEMBL5712524 | 0.81 | HSD11B1 (0.48) | HSD11B1ALDH1A1MAPT | |
| SCHEMBL9360098 | 0.80 | ALDH1A1 (0.67) | HSD11B1GAAALDH1A1MAPT | |
| SCHEMBL2901763 | 0.80 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL196799 | 0.79 | MEN1 (0.48) | HSD11B1ALDH1A1 | |
| SCHEMBL22021476 | 0.79 | ALDH1A1 (0.71) | HSD11B1GAAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735275-B1 | ARYL SULFONES AND USES RELATED THERETO | AMGEN INC (US) | 2010-08-18 | — | — | EP | claimed |
| US-20080269283-A1 | ARYLSULFONES AND USES RELATED THERETO | AMGEN INC. | 2008-10-30 | — | — | US | claimed |
| US-7402704-B2 | Arylsulfones and uses related thereto | AMGEN INC. (US) | 2008-07-22 | — | — | US | claimed |
| EP-1735275-A2 | ARYL SULFONES AND USES RELATED THERETO | Amgen Inc. (US) | 2006-12-27 | — | — | EP | claimed |
| US-20050277665-A1 | e.g. 1,1,1-trifluoro-2-[4-(toluene-2-sulfonyl)phenyl]-propan-2-ol; hydroxysteroid dehydrogenases inhibitor; interconversion between cortisone and cortisol in humans; antidiabetic agent; obesity, insulin resistance, non-insulin -dependent diabetes | AMGEN INC. | 2005-12-15 | — | — | US | claimed |
| WO-2005110980-A2 | ARYL SULFONES AND USES RELATED THERETO | AMGEN, INC. (US) | 2005-11-24 | — | — | WO | claimed |
| EP-1735275-B1 | ARYL SULFONES AND USES RELATED THERETO | AMGEN INC (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7754890-B2 | Arylsulfones and uses related thereto | AMGEN INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20080269283-A1 | ARYLSULFONES AND USES RELATED THERETO | AMGEN INC. | 2008-10-30 | — | — | US | disclosed |
| US-7402704-B2 | Arylsulfones and uses related thereto | AMGEN INC. (US) | 2008-07-22 | — | — | US | disclosed |
| EP-1735275-A2 | ARYL SULFONES AND USES RELATED THERETO | Amgen Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20050277665-A1 | e.g. 1,1,1-trifluoro-2-[4-(toluene-2-sulfonyl)phenyl]-propan-2-ol; hydroxysteroid dehydrogenases inhibitor; interconversion between cortisone and cortisol in humans; antidiabetic agent; obesity, insulin resistance, non-insulin -dependent diabetes | AMGEN INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005110980-A2 | ARYL SULFONES AND USES RELATED THERETO | AMGEN, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| EP-0911153-B1 | Image forming method | KONISHIROKU PHOTO IND (JP) | 2003-12-10 | — | — | EP | disclosed |
| US-6174646-B1 | IMAGEWISE HEATING OR EXPOSING IMAGE FORMING MATERIAL TO LASER WHEREIN IMAGE FORMING MATERIAL COMPRISES SUPPORT HAVING RADIATION SENSITIVE LAYER CONTAINING DYE, AN ACID GENERATING COMPOUND CAPABLE OF GENERATING ACID ON IRRADIATION | KONICA CORPORATION (JP) | 2001-01-16 | — | — | US | disclosed |
| EP-0911153-A1 | Image forming method | KONICA CORPORATION (JP) | 1999-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269283-A1 | ARYLSULFONES AND USES RELATED THERETO | ARSA, SULT2A1, UGT2B7 | HSD11B1 108/4885GAA 221/4885ALDH1A1 128/4885 |
| US-20050277665-A1 | e.g. 1,1,1-trifluoro-2-[4-(toluene-2-sulfonyl)phenyl]-propan-2-ol; hydroxysteroid dehydrogenases inhibitor; interconversion between cortisone and cortisol in humans; antidiabetic agent; obesity, insulin resistance, non-insulin -dependent diabetes | HSD17B1, HSD3B1, HSD11B1 | HSD11B1 3/4885GAA 868/4885ALDH1A1 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.